Evotec stock trades at EUR 2.61 with EUR 0.5 billion market value

Published on 10/12/2026 at 14:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec stock is valued at EUR 2.61 on October 12, 2026, versus EUR 2.77. Berenberg's EUR 3.60 target sits 37.93 percent above the price.

Key points in brief

Evotec stock traded at EUR 2.61 at Lang & Schwarz on October 12, 2026, 5.78 percent below the October 9 Xetra close of EUR 2.77.
Evotec's market capitalization was EUR 0.5 billion, with a 52-week range of EUR 2.57 to EUR 7.30.
Berenberg maintained a Hold rating and a EUR 3.60 target on September 25, 2026.
Evotec is listed on Xetra and is a member of the MDAX.

Trading-Floor mit großen Bildschirmen, Aktiencharts und dem Index-Kürzel MDAX — Börsen-Editorial mit Handelssaal und MDAX-Charts illustriert das Marktumfeld von Evotec SE, ISIN DE0005664809, im Biotech-Sektor, Illustration mit AI erstellt.

Evotec (ISIN DE0005664809) was trading at EUR 2.61 at Lang & Schwarz on October 12, 2026 at 2:32 p.m. CEST, 5.78 percent below the Xetra close of October 9, 2026 at EUR 2.77. The market capitalization was EUR 0.5 billion, giving the biotechnology company a compact valuation profile despite its MDAX membership.

Trading range remains wide

The 52-week range ran from EUR 2.57 to EUR 7.30 as of October 12, 2026. At EUR 2.61, the stock was EUR 4.69 below the high, while the current quote remained EUR 0.04 above the low.

The session data also show a sharp contrast with the larger German health care names. Evotec's volume was 1,872,113 shares against an average volume of 1,015,961, making turnover 84.27 percent higher than the average supplied for the instrument.

Valuation and analyst view

Evotec's trailing price-to-earnings ratio was minus 2.33 as of October 12, 2026, while the trailing dividend yield was 0.00 percent. The negative ratio reflects the company's loss-making earnings base rather than a conventional earnings multiple.

Markets Insider reported on September 25, 2026 that Berenberg analyst Christian Ehmann maintained a Hold rating and set a EUR 3.60 price target. The target lies 37.93 percent above the Lang & Schwarz price, using the same euro currency.

Comparison with peers

Evotec (Xetra, EUR): minus 5.78 percent, P/E minus 2.33, market capitalization EUR 0.5 billion

Sartorius (Xetra, EUR): plus 1.42 percent, P/E 90.46, market capitalization EUR 17.7 billion

Bayer (Xetra, EUR): plus 0.25 percent, P/E minus 24.92, market capitalization EUR 43.1 billion

Next results date is November 5

Boerse Express reported on October 6, 2026 that Evotec planned to publish its third-quarter and nine-month interim information on November 5, 2026. That date is the next scheduled company reporting point cited in the market coverage.

finanzen.ch identifies Evotec as a Xetra-listed biotechnology company with ticker EVT and MDAX membership. The listing context separates the German euro quote from the company's operating results and analyst estimates.

Price sets the market report tone

Evotec's EUR 2.61 quote at Lang & Schwarz on October 12, 2026 at 2:32 p.m. CEST stood 5.78 percent below the Xetra close of October 9, 2026 at EUR 2.77. The further course of trading is shown by the continuously updated real-time quote of Evotec stock.